Chris LeMasters, Corporate Development, Chimagen Biotherapeutics
Chris LeMasters who joined Chimagen Biotherapeutics in April 2024, currently serves as the chairman of both MBrace Therapeutics and Khartis Therapeutics, as well as a board member at Hoosier Cancer Research Network. Chris LeMasters was CEO of XinThera, a wholly owned subsidiary of Gilead, following its successful sale in May 2023. Previously, he was COO of Amplyx Pharmaceuticals, where led the strategic efforts that resulted in the company’s acquisition by Pfizer in April 2021. Prior to Amplyx, Mr. LeMasters was CBO of Mirati Therapeutics, where he was responsible for corporate development, strategy, and investor relations. During his three years in that role, he helped lead the successful expansion of the company and its market capitalization from $100 million in 2016 to over $5 billion in January 2020. Mr. LeMasters also served as the CEO of Promosome, a privately held mRNA re-engineering company founded by Nobel Laureate Dr. Gerald M. Edelman. He has co-founded and served as a management team member for several biotherapeutics companies, including Cabrellis Pharmaceuticals (acquired by Pharmion), Conforma Therapeutics (acquired by Biogen IDEC), Tragara Pharmaceuticals (acquired by Cothera), and Aarden Pharmaceuticals. Earlier in his career, Mr. LeMasters worked in the corporate business development group at Eli Lilly & Company and as a management consultant with Coopers & Lybrand and Owens-Corning. Mr. LeMasters currently serves as a board member of the Hoosier Cancer Research Network, a clinical research organization. He received his MBA from the University of Chicago and BS from Indiana University.